Publication of Torrey phase II results in the Lancet Respiratory Medicine

The paper, titled "Seralutinib in Adults with Pulmonary Arterial Hypertension (TORREY): A Randomized, Double-blind, Placebo-controlled Phase II Trial," details the study's significant findings in advancing the treatment of PAH.

TORREY was a Phase II, randomized, multicenter, multinational, double-blind, placebo-controlled study, evaluating the efficacy and safety of Gossamer’s novel therapy, seralutinib, in patients with PAH, a progressive condition that can lead to right heart failure and significantly reduces quality of life. 86 patients were randomized to receive either seralutinib or placebo by dry powder inhaler twice daily for 24 weeks. The results demonstrated a statistically significant improvement for seralutinib compared to placebo in the primary endpoint, reduction of pulmonary vascular resistance (PVR), and other important measures of disease, including measures of right heart structure and function.

Following the successful completion of TORREY, seralutinib was progressed into the ongoing global, registrational Phase III PROSERA Study for the treatment of PAH in WHO Functional Class II and III PAH patients (PROSERA). Details about PROSERA can be found here: https://clinicaltrials.gov/ct2/show/NCT05934526.

See-"Seralutinib in adults with pulmonary arterial hypertension (TORREY): a randomised, double-blind, placebo-controlled phase II trial"- Prof Robert P Frantz, MD . Prof Vallerie V McLaughlin, MD. Prof Sandeep Sahay, MD. Prof. Pilar Escribano Subías, MD. Prof Ronald L Zolty, MD. Prof Raymond L Benza, MD et al. Published:May 02, 2024DOI:https://doi.org/10.1016/S2213-2600(24)00072-9.